TMSB10 and neoplasm: As shown in Fig. 1G, TMSB10 and TMSB4X expression were higher in patients with the C2 and C6 subtypes, which indicate a poorer prognosis, suggesting that TMSB10 and TMSB4X might be involved in tumor immune deregulation.